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Abstract
Background: Drug resistance remains a great challenge in the treatment of gastric cancer. The goal of this study
was to explore the anti-tumor effects and mechanism of cytokine-induced killer (CIK) cell combined with oxaliplatin
(L-OHP) in human oxaliplatin-resistant gastric cancer cells.
Methods: After producing oxaliplatin-resistant gastric cancer cells, cell morphology, growth and doubling time
were observed, followed by detection of cell cycle distribution and apoptosis, drug sensitivity (e.g., L-OHP) and
expression of P-gp and livin. MTT assay, in vivo pharmacodynamics and pathomorphology experiments were used
to detect killing activities of CIK combined with L-OHP.
Results: Compared with parental gastric cancer cells, oxaliplatin-resistant gastric cancer cells in S phase were
reduced and cell apoptosis rate was increased (P < 0.05), the inhibition rate of 10 chemotherapeutics on
oxaliplatin-resistant gastric cancer cells was significantly lower and the expression of P-gp was significantly higher
(P < 0.05). However, there was no significant difference in livin expression between parental gastric cancer cells
and oxaliplatin-resistant gastric cancer cells (P > 0.05). The in vitro killing activity of CIK combined with L-OHP on
parental cells and oxaliplatin-resistant cells were significantly enhanced compared with L-OHP or CIK alone. And it
showed greater synergetic effects against oxaliplatin-resistant cells compared with parental cells (P < 0.05). In
addition, survival rate, abdominal circumference and pathomorphology results revealed stronger in vivo anti-tumor
effects when the two therapies were combined.
Conclusions: The mechanism of oxaliplatin-resistant cell secondary multidrug resistance was correlated with the
variation of cell cycle distribution, extension of doubling time and upregulation of P-gp expression. The synergistic
effect of CIK in combination with L-OHP on killing activity against oxaliplatin-resistant cells was shown in vivo and
in vitro.
Background
In addition to surgery, chemotherapy is the most effec-
tive adjuvant therapy for recurrent and metastasized
malignant tumors. Although current chemotherapy pro-
g r a m sc o n t i n u et oi m p r o v e ,i n d i v i d u a ld i f f e r e n c e so f
tumor patients in the sensitivity to chemotherapeutics
have led to chemotherapeutic efficacy in most patients
remaining unsatisfactory. Even within an individual, the
same drug can have differing effects during different
stages of cancer. Multidrug resistance (MDR) is consid-
ered as one of the main disturbances affecting che-
motherapeutic effects. Drug-resistant protein that
induces MDR was always over-expressed within medica-
tion, shown to render chemotherapeutics unable to
enter the effector target (i.e., the nucleus), leading to the
failure of chemotherapy.
Currently, platinum family is the powerful chemother-
apy drug widely used in clinical. Cisplatin (CDDP)
showed excellent therapeutic effects on various tumors
in several organs, including lung, ovary, bladder, pate,
esophagus, cervix, endometrium and testis [1]. Addition-
ally, oxaliplatin (L-OHP) was regarded as a third genera-
tion novel type of platinum compounds following CDDP
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with a bulky diaminocyclohexane (DACH) ring [2] and
showing specific properties of high efficiency and low
toxicity [3,4]. Moreover, L-OPH was shown to be effec-
tive in primary CDDP- and carboplatin-resistant colon
carcinoma and some secondary CDDP-resistant malig-
nant tumors [5-7]. Gastric cancer is a common alimen-
tary canal malignant tumor, which shows both primary
and secondary drug resistance. Chen et al. considered
that the drug-resistant mechanisms of gastric cancer to
L-OHP and CDDP were correlated with augmentation
of DNA repair and ATP7A overexpression [8]. MDR
mechanisms of gastric cancer cells were detected to aid
in choosing effective anti-cancer drugs, and individua-
lized treatment plans were made, resulting in improved
gastric therapeutic effects.
With the rapid developments in the field of tumor
immunology, use of immune effector cells, including
lymphokine-activated killer (LAK), tumor-infiltration
lymphocyte (TIL), anti-CD3 antibody induced activated
killer (CD3AK) and cytolytic T lymphocyte (CTL) cells,
on certain advanced-stage tumors has shown therapeutic
effects [9], and this treatment could kill remnant che-
motherapy-resistant tumor cells [10]. Cytokine-induced
killer (CIK) cells are a novel type of immunocompetent
cells with highly efficient and broad-spectrum anti-
tumor activity. These cells have been shown to prolifer-
ate among and directly kill CD3
+CD56
+ tumor cells in
vitro [11-13]. Furthermore, CIK cells were shown to
enhance cellular immune function in hosts [14,15], and
previous studies showed the killing activity of CIK cells
on MDR tumor cells was similar or greater than that on
parental drug-sensitive tumor cells [16,17]. This treat-
ment is thought to be effective for patients with recur-
rent tumors when combined with chemotherapy
[10,18-20].
In this study, the human oxaliplatin-resistant gastric
cancer cell line OCUM-2MD3/L-OHP was established,
and the relationships between cell biological characteris-
tics, the drug-resistant protein P-gp, and relationship
between the apoptosis-suppressor gene livin and MDR
in gastric cancer were investigated. Moreover, in vivo
and in vitro anti-tumor effects and mechanisms of CIK
combined with L-OHP on OCUM-2MD3/L-OHP cells
were explored to provide experimental evidence for clin-
ical application of CIK cells combined with chemother-
apy in the treatment of drug-resistant gastric cancer.
Materials
Main instruments
The following instruments were used in this study: a
-80°C ultra-low temperature refrigerator (SANYO,
Japan), a -152°C Ultra-low temperature freezer (SANYO,
Japan), an HT2 enzyme-linked immunosorbent assay
(ELISA) reader (Anthos, Austria), an Epics-XL-II flow
cytometer (Becoman Coulter, USA), a Diaphot 300
inverted phase contrast microscope (Nikon, Japan) and
an H-7500 transmission electron microscope (Hitachi,
Japan).
Main reagents
The following reagents were used in this study: mouse-
anti-human P-gp monoclonal antibody (ZSchem,
Peking), rabbit-anti-human Livin monoclonal antibody
(IMGENEX, USA), goat-anti-mouse fluorescent-labeled
antibody and goat-anti-rabbit fluorescent-labeled anti-
body (Sino-American Biotech.).
Cell culture
The human gastric cancer high invasion and metastasis
cell line OCUM-2MD3 (parent cell line) was a gift from
a professor in Surgical Department I of Osaka Medical
University in Japan.
The human oxaliplatin-resistant gastric cancer high
invasion and metastasis cell line OCUM-2MD3/L-OHP
(resistant cell line) was constructed and cultured in our
lab. The large dose (1.83 μg/ml) of L-OHP 24 h-repeated
intermittent exposure method was applied as follows:
DMEM medium containing L-OHP (1.83 μg/ml) was
added to cells in logarithmic phase, fresh culture medium
was replaced 24 h later, and this procedure was repeated
until cells recovered growth. Death of the sensitive cells
gradually appeared during induction, and the drug-resis-
tant cells were grown continuously for six months. Cells
were then cultured for two weeks with no drugs, IC50
values were gradually stabilized by detection of MTT
(methyl thiazolyl tetrazolium) rapid colorimetry and cells
were maintained in culture medium with no drugs. After
cryopreservation and recovery of 10% DMSO culture
medium, IC50 values were unchanged, indicating stabiliza-
tion of drug resistance. All drug-resistance experiments
were performed two weeks later in drug-free cultures.
The two cell types were cultured in DMEM medium
containing 10% fetal bovine serum, 100 μ/mL penicillin
and 100 μ/mL streptomycin at 37°C in a humidified incu-
bator containing 5% CO2. Cells in logarithmic phase were
collected to prepare single-cell suspensions.
Experimental drugs
The following experimental drugs were used in this
study: L-OHP (Jiangsu Hengrui Medicine Co., Ltd.),
0.9% physiological saline diluted at concentrations of
1200 μg/mL, 600 μg/mL, 300 μg/mL, 150 μg/mL and
75 μg/mL, Irinotecan (IH), Gemcitabine (GEM) (IH and
GEM obtained from Jiangsu Hengrui Medicine Co.,
Ltd.), cis-Diaminedichloroplatinum (CDDP), Carboplatin
(CBDAC) (QILU Pharmaceutical Co., Ltd.), Mitomycin
(MMC), Adriamycin (ADR) (MMC and ADR obtained
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tine (VCR), Paclitaxel (PTX) (VCR and PTX obtained
from Shanghai Hualian Pharmaceutical Factory) and 5-
flurouracil (5-FU) (Shanghai Xudong Pharmaceutical
Co., Ltd.).
Effector cells
Preparation and in vitro amplification of CIK cells: The
periphery heparin from healthy adults was obtained for
anticoagulation, and prepared according to a previous
report by Schmidt-Wolf IG et al. [17], cells were har-
vested in the 14
th day, and the ratio of potency and tar-
get was adjusted to 40:1, 20:1 or 10:1 before use.
Construction and grouping of the human gastric cancer
OCUM-2MD3/L-OHP cell peritoneal transplantation model
Preliminary experiments using our assay confirmed that
the incidence of peritoneal tumors was 100% when each
Balb/c nude mouse (female, 4~6 week, 15~18 g, animal
licenses lot: SCXK 11-00-0005) was inoculated intraperito-
neally with 5 × 10
6 drug-resistant cells. In our experiment,
35 nude mice were selected and inoculated intraperitone-
ally with drug-resistant cells at a dose of 5 × 10
6 cells per
0.2 ml each, and the human gastric cancer drug resistant
cell peritoneal transplantation model was established. All
mice were randomly divided into seven groups, including
the normal control, NS control, L-OHP (1.125 mg/kg,
2.25 mg/kg), CIK (2 × 10
7/0.2 mL, 4 × 10
7/0.2 mL) and
L-OHP+CIK groups. Intraperitoneal injection of drug-
resistant cells was performed in the first six groups after
15 days of inoculation, once every other day for a total of
three injection days. L-OHP (1.125 mg/kg) was adminis-
tered to the L-OHP+CIK group after inoculation for
15 days, then CIK cells (2 × 10
7/0.2 mL/number) were
injected intraperitoneally twice every other day for a total
of three injection days.
Methods
Observation of cell biological characteristics of OCUM-
2MD3/L-OHP (Parental cells were used as control)
Cell morphology observation of drug-resistant cells
Both cell types were cultured on culture plates and
observed under an inverted phase contrast microscope
until the cells covered 80% of the bottom wall. Cells
were collected (1 × 10
7 ), fixed with 2.5% glutaraldehyde
followed by 2% osmium tetroxide, dehydrated,
embedded, sectioned, stained and observed and photo-
graphed with a transmission electron microscope.
Growth curve of OCUM-2MD3/L-OHP cells by cell count
method
The two cell types were inoculated into 24-well plates at
a density of 1.5 × 10
4 cells/well and cultured at 37°C in
a humidified incubator containing 5% CO2.T h r e ew e l l s
were used for live-cell counts each day, and a cell-
growth curve was plotted after counting cells continu-
ously for six days. Doubling time was calculated with
the following equation: Td(h) = T × [log2/(logN-logN0)]
(Td represents doubling time, T represents time in loga-
rithmic proliferative phase (h), N represents cell num-
bers at the end of logarithmic proliferative phase, N0
represents cell numbers at the beginning of logarithmic
proliferative phase).
Cell cycle distribution and apoptosis of drug-resistant cells
analyzed by FCM (flow cytometry)
The two cell types (1 × 10
6/ml) were collected, washed
twice in PBS, fixed overnight with 70% cold ethanol and
washed twice in PBS. Next, 10% chicken red blood cells
were added as an internal control standard, 1 mL of
propidium iodide (PI) (50 mg/L) was added, cells were
kept at 4°C for 30 min, and FCM detection was per-
formed after filtration by 500-mesh copper grid.
Detection of drug sensitivity in drug-resistant cells by MTT
assay
Determination of sensitivity and resistance index (RI)
of drug-resistant cells to L-OHP A single-cell suspen-
sion of 5 × 10
4 cells/ml (200 μl/well) was added to a 96-
well culture plate, and the culture medium containing
L-OHP was added at final concentrations of 0.3, 0.6,
1 . 2 5 ,2 . 5 ,5 ,1 0a n d2 0μg/ml. Each concentration was
tested in triplicate wells, and cells were cultured at 37°C
in a humidified incubator containing 5% CO2 for 24 h.
The supernatants were then discarded and 200 μlo f
serum-free medium and 20 μl of MTT (5 mg/L) were
added in each well. Cells were cultured for 4 h, then
supernatants were discarded, and 150 μlo fD M S Ow a s
added to each well. The absorbance value of each well
was measured by an automatic ELISA reader at a wave-
length of 570 nm, and the inhibition rate and IC50 value
of L-OHP at different concentrations were calculated
according to the following equation: RI = IC50 (drug-
resistant cell)/IC50 (parental cell).
Detection of MDR and cross resistance in drug-resis-
tant cells A single-cell suspension of 5 × 10
4 cells/ml
(200 μl/well) was added to a 96-well culture plate, and
the culture medium containing the chemotherapeutics
L-OHP, CDDP, CBDCA, 5-Fu, ADM, MMC, GEM,
VCR, IH and PTX were added at final concentrations of
5.4, 12.6, 695.0, 40.0, 6.2, 1.0, 66.0, 0.08, 72.9 and
11.6 μg/mL, respectively. Each drug was tested in tripli-
cate. Cells were cultured at 37°C for 24 h in a humidi-
fied incubator containing 5% CO2, Supernatants were
then discarded and 200 μlo fs e r u m - f r e em e d i u ma n d
20 μl of MTT (5 mg/L) were added to each well. Cells
were cultured for 4 h, the supernatants were discarded,
and 150 μl of DMSO was added in each well. The
absorbance value of each well was measured by an
Zhao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:118
http://www.jeccr.com/content/29/1/118
Page 3 of 13automatic ELISA reader at a wavelength of 570 nm, the
inhibition rate of each drug was calculated, and an inhi-
bition rate less than 50% was set as the criteria for drug
resistance.
Expression of P-gp and Livin in drug-resistant cells detected
by FCM
The two cell types (each at a density of 1 × 10
6/ml)
were collected, washed in PBS twice, fixed overnight
with 70% cold ethanol, and again washed in PBS twice.
Cells were then incubated in 0.1 ml of mouse-anti-
human P-gp and rabbit-anti-human Livin monoclonal
antibodies at room temperature for 30 min and washed
in PBS. The supernatants were discarded, 100 μlo f
goat-anti-mouse or goat-anti-rabbit fluorescent antibody
was added according to the different detection index,
incubated away from light at room temperature for 30
min, washed in PBS, and FCM detection was performed
after filtration with a 500-mesh copper grid.
Detection of in vitro killing activity by CIK combined with
L-OHP on OCUM-2MD3/L-OHP cells
Groups (parent cells were set as controls for each group)
L-OHP intervention group The in vitro killing activities
of L-OHP applied alone at different concentrations
against drug-resistant cells at 24 h, 48 h and 72 h were
calculated.
CIK cell intervention group The in vitro killing activ-
ities of CIK cells alone with different ratios of potency
to target on drug-resistant cells were measured at 12 h,
24 h and 48 h.
CIK cell plus L-OHP intervention group CIK cells with
a ratio of potency to target of 40:1 were added for 12 h,
and L-OHP at different concentrations was then added.
The in vitro killing activities of combination of CIK and
L-OHP applied in drug-resistant cells were measured 24
h later.
Detection of in vitro killing activity of L-OHP on drug-
resistant cells
The two cell types (each at a density of 1 × 10
6/ml)
were collected and inoculated on 96-well plates (100 μl/
well, 1 × 10
5 counts), and the drugs were added 24 h
after cell adhesion.
L-OHP solutions were added (100 μl/well at final con-
centrations of 600, 300, 150, 75, and 37.5 μl/ml). The
same volume of culture medium was added in the con-
trol group, and all treatments were tested in triplicate.
Cells were cultured at 37°C in a humidified incubator
containing 5% CO2 f o r2 4h ,4 8ho r7 2h ,a n d2 0μlo f
MTT (5 mg/L) was then added to cultures.
Cells were cultured for 4 h then supernatants were
discarded, and 150 μl of DMSO was added to each well.
The absorbance value of each well was measured by an
ELISA reader at a wavelength of 570 nm, and killing
activity was calculated by the following equation from
which IC50 values were calculated:
Killing activity (%) = (mean OD value in control group
- mean OD value in experiment group) / (mean OD
value in control group - mean OD value in blank con-
trol group) × 100%
Detection of in vitro killing activity of CIK on drug-resistant
cells
The two cell types (each at a density of 1 × 10
6 cells/ml)
were collected, inoculated in 96-well plates (100 μl/well,
1×1 0
5 cells), and CIK cells were added 24 h after cell
adhesion.
CIK cells at different ratios of mixture Effector to Target
(40:1, 20:1, 10:1) were added to a 96-well plate (100 μl/
well). The same volume of culture medium was added in
the control group, and blank control wells were also used.
All treatments were tested in triplicate, and cells were cul-
tured at 37°C in a humidified incubator containing 5%
CO2 for 24 h, 48 h and 72 h. OD values were obtained by
MTT assay with an automatic ELISA reader at a wave-
length of 570 nm.
Detection of in vitro killing activity of CIK cells plus L-OHP
on drug-resistant cells
CIK cells were added at an E to T ratio of 40:1 for 12 h.
Various concentrations of L-OHP were then added, cells
were cultured for 24 h continuously, and the killing
activity of CIK and L-OHP was calculated.
Anti-tumor effect of CIK plus L-OHP in the human drug-
resistant gastric cancer cellular peritoneal transplantation
model
Tumor weight and abdominal circumference were mea-
sured 21 days postinoculation (i.e., 7 days after intraperi-
t o n e a la d m i n i s t r a t i o n ) .T h em i c ew e r es a c r i f i c e d ,a n d
the number of ascites was calculated. The criterion for
being cured was 60-day survival after inoculation with
tumor cells.
Pathomorphological observations in the human drug-
resistant gastric cancer cellular peritoneal transplantation
model after the treatment of L-OHP and CIK cells
Tissue sections were acquired 24 h after final injection
in each group, and macroscopic observation was used to
detect changes of peritoneal transplantation nodules.
The transplantation nodules in the omentum majus of
each mouse were selected and divided into two sections,
which were then used for routine pathological section-
ing and transmission electron microscope examination.
Statistical analyses
All data are expressed as mean ± SD, and analyses were
carried out using SPSS 12.0 software (SPSS Inc, Chicago,
IL). One-way analyses of variance (ANOVA), homoge-
neity tests for variance and Student’s t-tests were used
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considered statistically significant.
Results
Cell biological characteristics of OCUM-2MD3/L-OHP cells
Morphological observations of drug-resistant cells
As is shown in Fig.1A and 1B, the two cell types in sus-
pension appeared round under an inverted phase con-
trast microscope. Following cell adhesion, cells appeared
spindle-shaped, were arranged in a single layer of differ-
ent sizes, and showed no significant difference in cell
morphology. The microvilli on the surface of parental
cells were quite abundant under a transmission electron
microscope, and the morphology of organelles in the
cytoplasm was normal. The nuclei of the cells appeared
abnormally large and were irregularly shaped. Moreover,
euchromatin was abundant, heterochromatin was lim-
ited, and the nucleolus was large and clearly visible (Fig.
1C). There was no significant difference in morphology
of drug-resistant cells compared with OCUM-2MD3
cells. (Fig. 1D).
Growth curve and population doubling time of drug-
resistant cells
As shown in Fig. 2, proliferation speed of drug-resistant
cells was slower than that of parental cells. The popula-
tion doubling time of drug-resistant cells was 27.0 ±
2.04 h by cell counts, which extended for approximately
3 h (P < 0.05).
Cell cycle distribution and apoptosis of drug-resistant cells
As shown in Table 1, Fig. 3 and Fig. 4, drug-resistant
cell numbers in G0/G1 and G2/M phase were increased,
whereas cell numbers in S phase were decreased, and
the apoptosis rate was increased (P < 0.05). When cells
were treated with L-OHP for 24 h, the drug-resistant
cells in S phase increased in numbers, and parental cells
in G2/M phase increased. That is, drug-resistant cells
were arrested in G2/M phase by L-OHP, and parental
cells were arrested in S phase. Meanwhile, apoptosis
rates of both cell types were significantly enhanced,
although the apoptosis rate in drug-resistant cells was
less than the rate in parental cells (P < 0.05).
Figure 1 A. OCUM-2MD3 cell (Phase contrast microscope × 400); B. OCUM-2MD3/L-OHP cell (Phase contrast microscope × 400); C.
OCUM-2MD3 cell (TEM × 5000); D. OCUM-2MD3/L-OHP cell (TEM × 5000).
Figure 2 Cell-growth curve of OCUM-2MD3/L-OHP.
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As shown in Fig. 5, with the rise of L-OHP concentra-
tion, inhibition rates of L-OHP on the two cell types
gradually increased, and the inhibition rate of L-OHP
on drug-resistant cells was significantly less than the
inhibition rate of parental cells (P < 0.05). IC50 values of
L-OHP on drug-resistant cells and parental cells at 24 h
were 8.32 μg/mL and 1.92 μg/mL, respectively. In addi-
tion, the RI value of drug-resistant cells in response to
L-OHP was 4.3. Following repeated passages, cryopre-
servation and recovery, the RI value remained stable.
Detection of MDR in drug-resistant cells
As is shown in Fig. 6, the inhibition rates of 10 che-
motherapeutics, including L-OHP, CDDP, CBDCA, 5-
F u ,A D M ,M M C ,G E M ,V C R ,I Ha n dP T H ,o nd r u g -
resistant cells were significantly less than inhibition rates
in parental cells (P < 0.01). An inhibition rate less than
50% was set as the criterion for drug resistance, and
parental cells showed drug resistance to MMC, VCR
and IH. The drug-resistant cells were not only resistant
to L-OHP, but their sensitivity to CDDP, ADM and
PTX was also degraded and showed cross-resistance to
CBDCA, 5-Fu, MMC, GEM, VCR and IH.
Expression of P-gp and Livin in drug-resistant cells
As shown in Table 2 and Fig. 7, expression of P-gp and
Livin was seen in both cell types. However, although
P-gp expression in the drug-resistant cell line was higher
than expression in the parental cells (P < 0.05), Livin
expression showed no significant difference in two cell
types (P > 0.05).
Table 1 Cell cycle distribution of OCUM-2MD3/L-OHP cells
Cell Cell cycle Apoptosis rate (%)
G0/G1 SG 2/M
Control group
OCUM-2MD3 47.93 ± 0.35 46.83 ± 2.31 5.22 ± 2.50 1.00 ± 0.11
OCUM-2MD3/L-OHP 66.03 ± 0.28* 10.4 ± 1.06* 23.25 ± 0.78* 5.21 ± 0.55*
Treatment group
OCUM-2MD3 24.80 ± 0.52 49.37 ± 1.59 25.77 ± 1.30
Δ 35.53 ± 0.73
OCUM-2MD3/L-OHP 50.80 ± 2.00 27.80 ± 0.86
Δ 21.40 ± 2.79 29.43 ± 0.91*
* Comparisons of different cells in the same group P < 0.05
Δ Comparisons of different cells in different groups P < 0.05
Figure 3 Cell cycle. (A). OCUM-2MD3/L-OHP (Control group); (B). OCUM-2MD3 (Control group); (C). OCUM-2MD3/L-OHP (Treatment group); (D).
OCUM-2MD3 (Treatment group).
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L-OHP on drug-resistant cells
In vitro killing activity of L-OHP on drug-resistant cells
As shown in Tables 3, 4, 5, resistances of drug-resistant
cells to L-OHP increased 3.2-, 3.3- and 2.0-fold at the
24 h, 48 h and 72 h time points, respectively, when
compared with the parental cells. The killing activity of
L-OHP on drug-resistant cells and parental cells at 48 h
was the most powerful, and killing activity increased
with rising L-OHP concentrations.
In vitro killing activity of CIK cells in drug-resistant cells
As shown in Fig. 8, the killing activity of CIK cells on
the two cell types peaked at 24 h and increased with the
enhanced ratio of potency and target. Furthermore, the
killing activity of CIK cells at each time point on drug-
resistant cells were significantly higher than the killing
activity of CIK cells on parental cells (P < 0.05). These
findings suggest that CIK cells show more powerful in
vitro killing activity on drug-resistant cells compared
with the parental cells.
In vitro killing activity of CIK cells plus L-OHP in drug-
resistant cells
As shown in Table 6, the in vitro killing activities of
CIK cells combined with L-OHP in drug-resistant cells
and parental cells were significantly enhanced when
compared with L-OHP or CIK cells alone (P < 0.05),
Figure 4 Cell apoptosis. (A). OCUM-2MD3/L-OHP (Control group); (B). OCUM-2MD3 (Control group); (C). OCUM-2MD3/L-OHP (Treatment group);
(D). OCUM-2MD3 (Treatment group).
Figure 5 Inhibition rate of various concentrations of L-OHP on
drug-resistant cells.
Figure 6 Inhibition rates of different chemotherapeutics in
drug-resistant cells.
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concentration. Compared with the parental cells, the in
vitro killing activity of CIK cells plus L-OHP in drug-
resistant cells showed greater synergetic lethal effects
(P < 0.05).
Detection of in vivo activity of CIK cells plus L-OHP on
drug-resistant cells
Effect of ascites and survival rate of L-OHP and CIK cells in
the human gastric cancer resistant cellular peritoneal
transplantation model
As shown in Table 7, survival rate for both the L-OHP
group (1.125 mg/kg, 2.25 mg/kg) and the CIK group (2
×1 0
7/0.2 mL, 4 × 10
7/0.2 mL) was significantly
extended, and abdominal circumference was significantly
reduced after treatment when compared with the NS
control group (P < 0.01). Likewise, survival rate in the
L-OHP plus CIK group was significantly further
extended following treatment, and abdominal circumfer-
ence was significantly further reduced compared with
the NS control group (P < 0.01). Finally, there were no
significant differences in either survival rate or abdom-
inal circumference between the dual-treated group and
the normal control group (P > 0.01).
Pathomorphological effects of L-OHP and CIK cells in the
human gastric cancer resistant cellular peritoneal
transplantation model
Light microscope observations As shown in Fig. 9(a, b,
c), the volume of cancer cells in the L-OHP group was
reduced, and tumor hyperblastosis remained active.
These data indicate that cell necrosis in the CIK cell
group increased, and interstitial lymphocytes infiltrated.
The cancer cell volume in the L-OHP+CIK group was
significantly reduced, and a significant quantity of
necrotic tissue and nested central necrosis were seen.
Transmission electron microscope observations As
shown in Fig. 9(d, e, f), the nuclear heterocytosome in
t h eL - O H Pg r o u ps h o w e ds l i g h tm a r g i n a t i o n .I na d d i -
tion, after mixing cultures of CIK cells and tumor cells,
Table 2 Expression of P-gp and Livin in drug-resistant
cells
Cell line Relative protein expression
P-gp Livin
OCUM-2MD3 466.46 ± 12.04 467.82 ± 2.20
OCUM-2MD3/L-OHP 547.97 ± 7.76* 454.91 ± 8.56
* Compared with parental cell line, P < 0.05
Figure 7 Expression of P-gp and Livin in drug-resistant cells. R: OCUM-2MD3 group; T: OCUM-2MD3/L-OHP group; K: OCUM-2MD3 group; J:
OCUM-2MD3/L-OHP group.
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gination appeared. Additionally, cytoplasmic swelling
and severe vacuolar degeneration were seen in the L-
OHP+CIK group. These findings suggest that cells in
the L-OHP, CIK cell, and L-OHP+CIK group showed
cancer cell necrosis, apoptotic changes and gradual
aggravation.
Discussion
Cell immunotherapy combined with chemotherapy for
synergetic treatment of malignant tumors has been
reported [18,19]. Although the 5-year survival rate for
gastric cancer has improved, recurrence and metastasis
remain the main factors affecting prognosis. Biochemical
modulation is conducted as a novel therapeutic method
applied in the clinic, whether this method increases the
survival rate of gastric cancer patients is of most impor-
tance. Previous studies indicated that CIK combined
with chemotherapy could provide a clinical benefit for
gastric cancer patients by limiting progression [20,21],
whereas studies on synergetic therapy for MDR tumors
have reported quite limited outcome. The mechanism
underlying the complementary killing effect of CIK cells
combined with oxaliplatin in human gastric cancer resis-
tant cells remains uncertain.
Biological characteristic of OCUM-2MD3/L-OHP cells
The mechanism of drug resistance in tumor cells is
quite complicated. Therefore, constructing an ideal
drug-resistant cell line in vitro remains the premise and
foundation for investigating drug-resistant mechanisms
of tumor cells. Currently, there are only two methods
for constructing drug-resistant tumor-cell lines available,
including the drug concentration increment sustainable
method and large dose medicine intermittent induction
method. The method of gradually increasing drug-con-
centration in a culture medium is quite different from
the repeated intermittent medication in clinical che-
motherapy [22]. A recent study showed that when iden-
tical tumor cells were induced with the same drug at
the same final concentration, but with different induc-
tion methods, drug-resistant cell lines with distinct
drug-resistant mechanisms were produced [23]. The
medication mode of large dose intermittent induction
method mimics the processes seen in clinical che-
motherapy. The drug-resistant cells induced with this
method can maintain stable resistance and cell biologi-
cal characteristics, even after being cultured for an
extended duration in a drug-free culture medium. This
feature is quite desirable for investigation of the drug-
resistant cells.
In this study, we applied the IC50 concentration of
L-OHP for 24 h (1.83 μg/ml) at the human gastric can-
cer cells according to the repeated intermittent exposure
method and constructed oxaliplatin-resistant cell line
OCUM-2MD3/L-OHP successfully. The RI of this cell
line against L-OHP was 4.3, and after repeated passages,
cryopreservation and recovery, the RI remained stable.
According to Snow criteria [24], this cell line showed
low drug resistance to L-OHP. The parental cells
showed drug resistance to MMC, VCR and IH, showing
characteristics of primary MDR. However, the induced
drug-resistant cells are cross-resistant to CBDCA, 5-Fu,
MMC, GEM, VCR and IH, but not L-OHP, showing
features of secondary MDR. Additionally, there were no
significant differences in morphology of the resistant
cells compared with parental cells. In the resistant cells,
the proliferation speed was slower, population doubling
Table 3 Cytotoxicity of L-OHP on OCUM-2MD3/L-OHP (μg/mL, %, x¯ ± S, 24 h)
Group 600 300 150 75 37.5 IC50
OCUM-2MD3 76.2 ± 1.1 69.3 ± 2.3 57.7 ± 1.3 44.2 ± 0.9 28.3 ± 2.6 111.3
OCUM-2MD3/L-OHP 60.6 ± 0.5* 42.6 ± 1.3* 35.5 ± 4.2* 19.9 ± 1.7* 6.4 ± 2.1* 354.4
*Compared with OCUM-2MD3 Group P < 0.05
Table 4 Cytotoxicity of L-OHP on OCUM-2MD3/L-OHP (μg/mL, %, x¯ ± s,4 8h )
Group 600 300 150 75 37.5 IC50
OCUM-2MD3 85.2 ± 0.9 74.6 ± 1.7 65.4 ± 2.1 51.2 ± 1.4 37.3 ± 2.2 71.2
OCUM-2MD3/L-OHP 72.4 ± 1.5* 52.7 ± 2.6* 43.5 ± 0.8* 26.4 ± 1.5* 9.8 ± 3.2* 235.2
*Compared with OCUM-2MD3 Group P < 0.05
Table 5 Cytotoxicity of L-OHP on OCUM-2MD3/L-OHP (μg/mL%, x¯ ± S, 72 h)
Group 600 300 150 75 37.5 IC50
OCUM-2MD3 50.2 ± 1.8 40.6 ± 1.5 25.4 ± 2.7 19.2 ± 1.4 8.3 ± 1.7 522.3
OCUM-2MD3/L-OHP 38.4 ± 1.1* 24.7 ± 2.3* 17.5 ± 2.5* 9.8 ± 1.5* 5.6 ± 3.2* 1057.0
*Compared with OCUM-2MD3 Group P < 0.05
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Page 9 of 13time was extended, and most cells were in G0/G1 phase.
However, L-OHP only affects tumor cells from S phase
to G2/M phase and may lead to attenuated chemothera-
peutic sensitivities in resistant cells, which is possibly
one of the mechanisms of secondary MDR.
The MDR gene MDR1 is located on 7q21.1 and
encodes the P-gp protein as a transmembrane protein,
which is composed of 1280 amino acid residues with a
molecular weight of 170 kD. Twelve transmembrane
domains and two ATP binding sites are located on the
P-gp protein, which enable the molecule function as an
energy-dependent drug-excretion pump, obstructing
passive diffusion of drugs to the cytoplasm by activating
an ATP pump. Additionally, P-gp can transport intracel-
lular cytotoxic drugs outside of the membrane by active
transport, leading to attenuation or deprivation of cyto-
toxic effects that generate the drug-resistance phenom-
enon and chemotherapeutic failure in the clinic [25].
The typical mechanism underlying MDR involves the
MDR1 gene and overexpression of P-gp. P-gp overex-
pression was the most prominent drug-resistance
mechanism generated in gastric cancer [26]. Our study
indicates that P-gp is expressed both in drug-resistant
cells and parental cells, and the expression of P-gp in
drug-resistant cells was significantly higher than that in
parental cells. Thus, we speculate that the secondary
MDR was associated with upregulated P-gp expression,
leading to drug resistance against L-OHP, CBDCA, 5-
Fu, MMC, GEM, VCR and IH. The detection of P-gp
expression levels in tumor tissues might help to choose
optimized chemotherapeutic plan, reduce toxic side
effects, and allow individualized chemotherapy.
Livin is a critical member of the apoptosis protein
inhibitor family and binds caspases to inhibit their activ-
ity [27]. This effect causes cells to lose capability of pro-
grammed cell death, resulting in an imbalance of cell
numbers in tissues and organs, and finally the formation
of tumors. There is a critical correlation between the
overexpression of livin and the impaired apoptosis
mechanism in malignant tumor cells leading to apopto-
sis tolerance. In recent studies, Livin overexpression was
found to be correlated with MDR mechanisms in multi-
ple human tumors, such as leukemia, liver cancer and
ovarian cancer [28-32]. In this study, we show that Livin
expression was expressed in both drug-resistant cells
and parental cells without significant difference, suggest-
ing no direct correlation with mechanisms of secondary
MDR.
In vivo and in vitro killing activity of CIK cells plus L-OHP
on OCUM-2MD3/L-OHP cells
Previous studies have shown that the overexpression of
P-gp in MDR tumor cells enhances the immunogenicity
of target cells, and makes the target cells more easily be
recognized by immune effector cells. Therefore, the
cytotoxic effect of immune effector cells against drug-
resistant tumor cells was similar or even stronger than
against parental cells. Moreover, maintenance of in vivo
cytotoxicity against tumor cells was not necessarily
dependent on the sustained administration of large
doses of exogenous interleukin (IL)-2 [16,33-35]. Appli-
cation of immunocytes, including CIK cells, may be a
feasible treatment for drug-resistant tumors, although
this treatment requires further investigation.
Figure 8 Cytotoxic activity of CIK cells against tumor cells.
Table 6 Cytotoxic activity of CIK cells plus L-OHP in OCUM-2MD3/L-OHP cells (μg/mL, %, x¯ ± S)
Group 600 300 150 75 37.5 IC50
OCUM-2MD3 90.2 ± 1.7 81.1 ± 1.5 75.5 ± 2.9 65.3 ± 3.3 42.6 ± 1.6 44.5
OCUM-2MD3/L-OHP 94.5 ± 0.7* 85.0 ± 2.4* 79.4 ± 2.1* 67.7 ± 1.2* 50.9 ± 3.4* 36.8
*Compared with the OCUM-2MD3 group, P < 0.05
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in vitro killing activity against drug-resistant cells than
against parental cells. The possible mechanism underly-
ing this phenomenon may be the CD3
+CD56
+ double
positive cells as cytoplasmic particles to kill tumor cells
released when CIK cells are stimulated. Additionally, a
large amount of inflammatory cytokines, such as TNF-
a, IL-2 and GM-CSF, are released by the activated CIK
cells, which can directly inhibit tumor cells, or indirectly
kill tumor cells by modulating the immune system.
Previous studies suggested that CIK cells play a critical
role in the accumulation of chemotherapeutic drugs in
MDR tumor cells, and that the killing activity of CIK
cells plus chemotherapeutic drugs against MDR tumor
cells was significantly higher than with chemotherapeu-
tic drugs along. Furthermore, the killing activity of CIK
cells is proportional to the ratio of effector cells to tar-
get cells. However, the in vivo killing activity cannot be
accurately measured [10]. Lack of this knowledge may
result in unsatisfactory immune therapeutic effects in
certain patients. The combination of immune effector
cells and chemotherapeutic drugs against MDR target
cells was able to improve the sensitivity of drug-resistant
cells to chemotherapeutic drugs. This dual treatment
showed excellent effects in scavenging remnant tumor
cells expressing drug-resistant proteins in postoperative
patients, even in drug-resistant tumors in middle and
advanced stages irresponsible to radiotherapy and
chemotherapy.
Our study revealed that the in vivo and in vitro killing
activity of CIK cells combined with various concentra-
tions of L-OHP against two types of tumor cells was
Table 7 Effect on the model of gastric cancer by L-OHP, CIK, L-OHP+CIK (x¯ ± S)
Group n Abdominal perimeter (cm) Existed time (d) Survival rate (35d)
Normal control group 5 8.8 ± 0.4 60 ± 0 5/5
NS control group 5 15.61 ± 0.5 20 ± 3.5 0/5
L-OHP1.125 mg/kg 5 14.45 ± 0.3
a 38 ± 4.2
a 3/5
a
L-OHP2.25 mg/kg 5 12.15 ± 0.2
a 52 ± 3.8
a 4/5
a
CIK2 × 10
7/0.2 mL 5 13.90 ± 0.2
a 40 ± 4.6
a 3/5
a
CIK4 × 10
7/0.2 mL 5 11.87 ± 0.2
a 53 ± 4.3
a 4/5
a
L-OHP+CIK 5 8.46 ± 0.3
ab 60 ± 0
ab 5/5
ab
a) P < 0.01 Compared with NS control group
b) P > 0.01 Compared with normal control group
Figure 9 Pathomorphological effects of L-OHP and CIK on the model of gastric cancer. a) Effect of L-OHP (4.5 mg/kg, HE × 100) on the
model of gastric cancer. b) Effect of CIK (4 × 10
7/0.2 mL, HE × 100) on the model of gastric cancer. c) Effect of L-OHP+CIK (HE × 100) on the
model of gastric cancer. d) Effect of L-OHP (2.25 mg/kg, EM, × 10.0 K) on the model of gastric cancer. e) Effect of CIK (2 × 10
7/0.2 mL, EM, × 7.0
K) on the model of gastric cancer. f) Effect of L-OHP+CIK (EM, × 7.0 K) on the model of gastric cancer.
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Page 11 of 13significantly enhanced in comparison with the use of L-
OHP or CIK cells alone. Moreover, the killing activity of
CIK cells combined with L-OHP against drug-resistant
cells showed stronger synergetic effects than the similar
treatment of parental cells, providing evidence of
improved anti-tumor effects for the clinical application
of CIK cells combined with L-OHP.
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